N-acetyl-6-nitro-1,2,3,4-tetrahydroisoquinoline | 174648-97-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: N-acetyl-6-nitro-1,2,3,4-tetrahydroisoquinoline
• 英文别名: 1-(6-Nitro-3,4-dihydroisoquinolin-2(1H)-yl)ethanone；1-(6-nitro-3,4-dihydro-1H-isoquinolin-2-yl)ethanone
• CAS: 174648-97-6
• 化学式: C₁₁H₁₂N₂O₃
• 分子量: 220.228
• InChiKey: SSDCKHDYPOBYCU-UHFFFAOYSA-N

物化性质

• 沸点：
  416.1±45.0 °C(Predicted)
• 密度：
  1.292±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  66.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-acetyl-6-nitro-1,2,3,4-tetrahydroisoquinoline 在 盐酸 作用下， 以 甲醇 为溶剂， 反应 10.0h， 生成 1,2,3,4-四氢-6-硝基异喹啉
  参考文献：
  名称：

  Synthesis and Flow Cytometric Evaluation of Novel 1,2,3,4-Tetrahydroisoquinoline Conformationally Constrained Analogues of Nitrobenzylmercaptopurine Riboside (NBMPR) Designed for Probing Its Conformation When Bound to the es Nucleoside Transporter

  摘要：

  Novel regioisomers of conformationally constrained analogues of the potent es nucleoside transporter ligand, nitrobenzylmercaptopurine riboside (NBMPR), designed for probing its bound (bioactive) conformation, were synthesized and evaluated as es transporter ligands by flow cytometry. Purine 6-position 5, 6, 7, or 8-nitro-1,2,3,4-tetrahydroisoquinolylpurine ribosides, in which the nitrobenzyl moiety in NBMPR has been locked into the nitro-1,2,3,4-tetrahydroisoquinoline system, were synthesized by reaction of the appropriate nitro-1,2,3,4-tetrahydroisoquinoline with 6-chloropurine riboside. Flow cytometry was performed using 5-(SAENTA)X8-fluorescein as the competitive ligand. A high degree of variation in the es transporter binding capacity of the target compounds was observed, with the K-i values ranging from 0.45 nM for the most tightly bound compound (4) to 300 nM for the least tightly bound compound (5). The Ki of NBMPR was 0.70 nM, a little higher than that of compound 4. Compound 4 is the isomer that has the nitro group in the best orientation at the es transporter binding site compared to the other three compounds, 2, 3, and 5.

  DOI：

  10.1021/jm020405p
• 作为产物：
  描述：

  1-(7-nitro-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one 在 盐酸 、 硫酸 、 三氯化铁 、 甲烷 、 potassium nitrate 、 三氟乙酸 、 sodium nitrite 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 23.41h， 生成 N-acetyl-6-nitro-1,2,3,4-tetrahydroisoquinoline
  参考文献：
  名称：

  Synthesis and Flow Cytometric Evaluation of Novel 1,2,3,4-Tetrahydroisoquinoline Conformationally Constrained Analogues of Nitrobenzylmercaptopurine Riboside (NBMPR) Designed for Probing Its Conformation When Bound to the es Nucleoside Transporter

  摘要：

  Novel regioisomers of conformationally constrained analogues of the potent es nucleoside transporter ligand, nitrobenzylmercaptopurine riboside (NBMPR), designed for probing its bound (bioactive) conformation, were synthesized and evaluated as es transporter ligands by flow cytometry. Purine 6-position 5, 6, 7, or 8-nitro-1,2,3,4-tetrahydroisoquinolylpurine ribosides, in which the nitrobenzyl moiety in NBMPR has been locked into the nitro-1,2,3,4-tetrahydroisoquinoline system, were synthesized by reaction of the appropriate nitro-1,2,3,4-tetrahydroisoquinoline with 6-chloropurine riboside. Flow cytometry was performed using 5-(SAENTA)X8-fluorescein as the competitive ligand. A high degree of variation in the es transporter binding capacity of the target compounds was observed, with the K-i values ranging from 0.45 nM for the most tightly bound compound (4) to 300 nM for the least tightly bound compound (5). The Ki of NBMPR was 0.70 nM, a little higher than that of compound 4. Compound 4 is the isomer that has the nitro group in the best orientation at the es transporter binding site compared to the other three compounds, 2, 3, and 5.

  DOI：

  10.1021/jm020405p

文献信息

• Hypoxia-Selective Antitumor Agents. 12. Nitrobenzyl Quaternary Salts as Bioreductive Prodrugs of the Alkylating Agent Mechlorethamine
  作者：Moana Tercel、William R. Wilson、Robert F. Anderson、William A. Denny

  DOI：10.1021/jm9507791

  日期：1996.1.1

  -358 mV and undergoes reductively-induced fragmentation to release the nitrogen mustard mechlorethamine. The compounds were prepared by halogenation (SOCl2) of the corresponding quaternary diols, which in turn were synthesized from N-methyldiethalnolamine and substituted nitrobenzyl chlorides. The reduction potentials of the benzene-substituted compounds were generally well-predicted by Hammett substituent

  新型低氧选择性细胞毒素N，N-双（2-氯乙基）-N-甲基-N-（2-硝基苄基）氯化铵（3a）的一系列苯取代类似物，以及三个相应的“环”四氢异喹啉鎓已经制备了类似物21a-23a和两种萘衍生物（19a和20a），并在有氧和低氧条件下评估了培养的哺乳动物肿瘤细胞的细胞毒性。母体化合物3a的单电子还原电势为-358mV，并经历还原诱导的裂解以释放芥菜甲氧乙胺氮。该化合物是通过相应的季二醇的卤化（SOCl2）制备的，而这些季二醇又是由N-甲基二乙二胺和取代的硝基苄基氯合成的。苯取代的化合物的还原电势通常通过哈米特取代基关系很好地预测。所有化合物对修复缺陷型UV4细胞的毒性都比相应的野生型AA8细胞高得多，这是预期的，如果活性细胞毒性物质用作DNA烷基化剂。与AA8相比，它们对人细胞EMT6和FME的毒性更大，但其原因尚不清楚。在苯环中被给电子取代基取代的3a类似物为低氧AA8细胞提供了广泛不同的选
• SAR studies of capsazepinoid bronchodilators. Part 2: Chlorination and catechol replacement in the A-ring
  作者：Magnus Berglund、María F. Dalence-Guzmán、Staffan Skogvall、Olov Sterner

  DOI：10.1016/j.bmc.2007.11.061

  日期：2008.3

  airways. From a systematic variation of the capsazepine structure, divided into four regions, SARs were established. This paper concerns the chlorination of the A-ring as well as the replacement of the catechol with bioisosteric groups. It is revealed that chlorination of the A-ring has a profound effect on activity. Moreover, di-chlorination of the 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline structure

  辣椒素及其衍生物和类似物是人类小气道收缩的一般抑制剂。从辣椒素结构的系统变化分为四个区域，建立了SAR。本文涉及A环的氯化以及生物等位基团取代邻苯二酚。揭示了A环的氯化对活性有深远的影响。此外，与卡塞平相比，对6,7-二羟基-1,2,3,4-四氢异喹啉结构进行二氯化处理会导致效力增加10倍。
• [EN] BRONCHORELAXING COMPOUNDS<br/>[FR] COMPOSES BRONCHO-RELACHANTS
  申请人：RESPIRATORIUS AB

  公开号：WO2005070887A1

  公开（公告）日：2005-08-04

  A compound of the general formula (I) including its pharmaceutically acceptable acid addition salts formula (I) wherein A is CHR9, wherein R9 is H, C1-C6 alkyl;n is 1-3; B is CHR10, wherein R10 is H, C1-C6 alkyl; m is 1 or 2; D is O or S; E is CR11R12 or NR13, wherein R11 and R12 are, independent of each other, H or C1-C6 alkyl, R13 is H or C1-C6 alkyl; F is C1-C18 alkyl or R4-R7 cycloalkyl, which may be mono- or di-unsaturated and/or substituted, is useful in treating and preventing pulmonary disease characterized by bronchoconstriction; also disclosed is a pharmaceutical composition comprising the compound of formula (I), a pharmaceutical carrier and, optionally, an anti-asthmatic, a method for its manufacture, and a method for treating or preventing such disease.

  通式（I）的化合物及其药学上可接受的酸加合盐，其中A为CHR9，其中R9为H，C1-C6烷基；n为1-3；B为CHR10，其中R10为H，C1-C6烷基；m为1或2；D为O或S；E为CR11R12或NR13，其中R11和R12独立地为H或C1-C6烷基，R13为H或C1-C6烷基；F为C1-C18烷基或R4-R7环烷基，可以是单烯或双烯和/或取代的，用于治疗和预防以支气管收缩为特征的肺部疾病；还公开了包含通式（I）的药物组合物、药物载体和可选的抗哮喘药、其制造方法以及治疗或预防该疾病的方法。
• Bronchorelaxing compounds
  申请人：Skogvall Staffan

  公开号：US20060040919A1

  公开（公告）日：2006-02-23

  A compound of the general formula (I) including its pharmaceutically acceptable acid addition salts wherein A is CHR 9 , wherein R 9 is H, C 1 -C 6 alkyl; n is 1-3; B is CHR 10 , wherein R 10 is H, C 1 -C 6 alkyl; m is 1 or 2; D is O or S; E is CR 11 R 12 or NR 13 , wherein R 11 and R 12 are, independent of each other, H or C 1 -C 6 alkyl, R 13 is H or C 1 -C 6 alkyl; F is C 1 -C 18 alkyl or R 4 -R 7 cycloalkyl, which may be mono- or di-unsaturated and/or substituted, is useful in treating and preventing pulmonary disease characterized by bronchoconstriction; also disclosed is a pharmaceutical composition comprising the compound of formula (I), a pharmaceutical carrier and, optionally, an anti-asthmatic, a method for its manufacture, and a method for treating or preventing such disease.

  化合物的一般式(I)及其药学上可接受的酸盐包括其中，其中A为CHR9，其中R9为H，C1-C6烷基；n为1-3；B为CHR10，其中R10为H，C1-C6烷基；m为1或2；D为O或S；E为CR11R12或NR13，其中R11和R12独立地为H或C1-C6烷基，R13为H或C1-C6烷基；F为C1-C18烷基或R4-R7环烷基，可以是单烯或双烯和/或取代的，用于治疗和预防以支气管收缩为特征的肺部疾病；还公开了包括式(I)化合物的药物组合物、药物载体和可选的抗哮喘药、其制造方法以及治疗或预防该疾病的方法。
• Novel Nucleoside Transport Inhibitors
  申请人：Buolamwini Kwesi John

  公开号：US20070293444A1

  公开（公告）日：2007-12-20

  Compounds or compositions that are inhibitors and/or ligands of nucleoside transporters; and methods of treating cancer, heart disease and stroke, as well as AIDS and other infectious diseases

  抑制核苷酸转运体的化合物或组合物；以及治疗癌症、心脏病和中风，以及艾滋病和其他传染病的方法。